Conference Program and Abstracts
Total Page:16
File Type:pdf, Size:1020Kb
10th Human Amyloid Imaging January 13-15, 2016 Miami, Florida Co-Organizers: Keith A. Johnson, MD ● William J. Jagust, MD ● William E. Klunk, MD, PhD ● Chester A. Mathis, PhD Conference Program and Abstracts www.worldeventsforum.com/hai TABLE OF CONTENTS 1 1, 2 1, PRESENTER INDEX ............................................ 10 Christopher Schwarz , Matthew Senjem , Jeffrey Gunter 2, Nirubol Tosakulwong3, Heather Wiste3, Stephen HAI2016 PROGRAM ............................................. 12 Weigand3, Bradley Kemp1, Anthony Spychalla1, Prashanthi Vemuri1, Ronald Petersen4, Val Lowe1, Clifford Jack1 ...... 23 Wednesday, January 13, 2016 – 1:15pm-2:30 ...15 Podium Presentations ............................................. 15 Principal component analysis of [18F]-AV-1451 tau SESSION 1: New Pet Ligands; Centiloids; Kinetic PET in sporadic Alzheimer’s disease and frontotemporal dementia ....................................................................... 24 Studies ...................................................................... 15 Karl Friedrichsen1, 6, Shruti Mishra1, 6, Brian Gordon1, 2, 6, Quantification, test-retest and dosimetry of the novel Tyler Blazey1, Nelly Joseph-Mathurin1, 6, Nupur Ghoshal1, 2, Genentech Tau Probe 1, [18F]GTP1 ............................ 16 3, Yi Su1, 6, Jon Christensen1, 6, Russ Hornbeck1, 6, Patricia Sandra Sanabria Bohorquez1, Olivier Barret2, Gilles Aldea1, Jonathan McConathy1, 6, Beau Ances1, 2, 3, Nigel Tamagnan2, David Alagille2, Simon Williams1, Alex de Cairns1, 2, 3, 5, John Morris1, 2, 3, Tammie Benzinger1, 2, 4, 6 .. 24 Crespigny1, Gai Ayalon1, Geoffrey Kerchner1, William 18 Cho1, Danna Jennings2, John Seibyl2, Ken Marek2, Robby Distinct patterns of [ F]THK-5351 retention in AD and Weimer1, Jan Marik1 .......................................................... 16 non-AD tauopathies ..................................................... 26 Nobuyuki Okamura1, 2, 3, Akio Kikuchi4, Katsutoshi Clinical evaluation of [18F]RO6958948, a new Furukawa5, Aiko Ishiki5, Ryuichi Harada1, Takafumi radioligand for imaging tau pathology in AD .............. 17 Hasegawa4, Atsushi Takeda6, Shozo Furumoto3, Ren Iwata3, Dean Wong1, 2, 3, Robert Comley4, Hiroto Kuwabara1, Noble Manabu Tashiro3, Kazuhiko Yanai2, 3, Masashi Aoki4, George1, Paul Rosenberg2, Constantine Lyketsos2, Madhav Hiroyuki Arai5, Yukitsuka Kudo1 ....................................... 26 Thambisetty5, Henner Knust4, Michael Honer4, Frank Boess4, Susanne Ostrowitzki4, Robert Dannals1, Edilio Thursday, January 14, 2016 - 08:00am - 09:00 .27 4 Borroni ............................................................................. 17 Podium Presentations ............................................ 27 Implementation and validation of the Centiloid SESSION 3: Pathology ........................................... 27 18 transformation for F-NAV4694 ................................. 18 Differences between lateral and medial PET image Christopher C. Rowe1, 2, Gareth Jones1, Svetlana Pejoska1, intensity for equivalent levels of Aβ pathology ........... 28 Vincent Doré3, 4, Laura Margison1, Rachel Mulligan1, Adrian Smith, Chris Buckley .............................................. 28 Pierrick Bourgeat4, J. Gordon Chan1, Olivier Salvado4, Colin L. Masters3, Victor L. Villemagne1, 2, 3 ...................... 18 Centiloid thresholds for amyloid positivity derived from autopsy-proven cases ................................................... 29 Quantification of the tau PET tracer [18F]AV-1451 with 1, 2 2 2 kinetic modeling ........................................................... 19 Nagehan Ayakta , Samuel Lockhart , James O'Neill , Rik Ossenkoppele1, Bruce Reed1, John Olichney3, Adam Boxer1, Olivier Barret1, David Alagille1, Sandra Sanabria2, Robert Bruce Miller1, Ewa Borys4, Lee-Way Jin5, Eric Huang1, Lea Comley3, Robby Weimer2, Edilio Borroni3, Nicholas Grinberg1, Charles DeCarli3, William Seeley1, William Seneca4, Abhinay D. Joshi5, Michael D. Devous5, Mark A. Jagust2, Gil Rabinovici1, 2 .................................................. 29 Mintun5, Danna Jennings1, Ken Marek1, John P. Seibyl1, Gilles D. Tamagnan1 .......................................................... 19 In vitro binding and histology analyses of a putative tau ligand T807 in AD and non-AD tauopathy cases ......... 31 Comparing tau measurements within tracers and 1 1 1 between ........................................................................ 20 Milos Ikonomovic , Eric Abrahamson , Manik Debnath , William Paljug1, Lan Shao1, William Seeley2, Chester Suzanne Baker1, Mark He2, Sam Lockhart2, Gil Rabinovici3, Mathis1, Gil Rabinovici2, William Klunk1 .......................... 31 Nobuyuki Okamura4, William Jagust1, 2 ............................. 20 Neuropathologic maturity of neurofibrillary tangles: Wednesday, January 13, 2016 - 3:40 - 4:40pm ..21 Implications for tau PET imaging ................................ 32 Podium Presentations ............................................. 21 Melissa Murray1, Geoffry Curran2, Amanda Liesinger1, SESSION 2: PET Data Analytics: Time Series, Mukesh Pandey2, Ping Fang2, Kejal Kantarci2, Bradley 2 2 1 Data Reduction, and THK5351 ............................. 21 Boeve , David Knopman , Leonard Petrucelli , Dennis Dickson1, Ronald Petersen2, Neill Graff-Radford1, Clifford Longitudinal changes in [18F]AV-1451 PET tau signal: Jack, Jr.2, Val Lowe2 .......................................................... 32 Interim analysis of a Phase 2 study .............................. 22 Mark Mintun, Michael Devous, Sr, Abhinay Joshi, Ian Thursday, January 14, 2016 - 09:40 - 10:25am & Kennedy, Michael Navitsky, Ming Lu, Andrew Siderowf, 3:10 - 3:55pm ........................................................33 Michael Pontecorvo ........................................................... 22 Poster Session (even-numbered) ........................... 33 Optimizing Florbetapir SUVR change over time Determination of smallest detectable difference for measurement ................................................................. 23 amyloid PET tracers using test-retest data ................... 33 1 Aniket Joshi1, Dai Feng2, Richard Baumgartner2 .............. 33 Imaging aggregates of amyloid and tau in dementia with Lewy bodies and Parkinson’s disease .......................... 42 Serum adiponectin levels and neuroimaging outcomes in the Mayo Clinic Study of Aging .................................. 34 Stephen Gomperts, Joseph Locascio, Sara Makaretz, Aaron Schultz, Brad Dickerson, John Growdon, Keith Johnson .. 42 Alexandra Wennberg1, Deborah Gustafson2, Clinton Hagen1, Rosebud Roberts1, 4, David Knopman4, Clifford Metabolite analysis of tau PET tracer [18F]THK-535143 Jack3, Ronald Petersen1, 4, Michelle Mielke1, 4 ................... 34 Ryuichi Harada1, Nobuyuki Okamura1, 2, Shozo Furumoto3, 3 4 4 The loss of functional and effective connectivity in mild Tetsuro Tago , Katsutoshi Furukawa , Aiko Ishiki , Ren 4 3 4 2, cognitive impairment is linked to amyloid deposition Iwata , Manabu Tashiro , Hiroyuki Arai , Kazuhiko Yanai 3, Yukitsuka Kudo1 ............................................................. 43 and ApoE4 .................................................................... 35 Lars Michels1, Muthuraman Muthuraman2, Abdul Rauf Tau imaging relationships with amyloid-beta imaging, Anwar2, Spyros Kollias1, Sandra Leh3, Florian Riese3, Paul CSF tau/Aβ42, and cognition in Alzheimer’s disease .. 44 Unschuld3, Michael Siniatchkin4, Anton Gietl3, Christoph Beau Ances1, Matthew Brier1, Brian Gordon2, Karl Hock3 .................................................................................. 35 Friedrichsen2, John McCarthy3, Ari Stern3, Yi Su2, Jason 1 1 1 Early AD detection: Performance of a new fast Hassenstab , Nigel Cairns , David Holtzman , Anne 1 1 2 hippocampus volumetry in comparison with automated Fagan , John Morris , Tammie Benzinger ....................... 44 11 voxel-based [ C]PiB PET quantitation ........................ 36 Higher cortical amyloid is associated with loneliness in Arthur Mikhno1, Janos Redei1, J John Mann2, 3, Ramin cognitively normal older adults .................................... 46 Parsey4 ............................................................................... 36 Nancy Donovan1, Victoria Jonas2, Patrizia Vannini1, 2, 2 2 1, 2 Prodromal AD: Utility of a new fast hippocampus Aaron Schultz , Elizabeth Mormino , Rebecca Amariglio , 1, 2 1, 2 1, 2 volumetry, in combination with APOE vs. MR-less- and Dorene Rentz , Olivia Okereke , Gad Marshall , Keith Johnson1, 2, Reisa Sperling1, 2 ............................................. 46 voxel-based [18F]florbetapir PET quantitation ............. 37 Arthur Mikhno1, Janos Redei1, J John Mann2, 3, Ramin Tau PET imaging in relation to amyloid β and Parsey4 ............................................................................... 37 neurodegeneration biomarkers in aging and AD .......... 47 The quest for a robust and reliable reference region Liang Wang, Tammie Benzinger, Yi Su, Jon Christensen, (RR): Exploring RR stability across clinical categories, Karl Friedrichsen, Jon McConathy, Nigel Cairns, Anne Fagan, John Morris, Beau Ances ...................................... 47 across Aβ status and across time for five different Aβ radiotracers ................................................................... 38 Contributions of age and Alzheimer’s pathology to Victor L. Villemagne1, 2, Pierrick Bourgeat3, Vincent Doré1, hippocampal memory network function in healthy